Sichenzia Ross Ference Kesner LLP Represents XTL Biopharmaceuticals Ltd. in $2.5 Million Registered Direct Offering
Press Release – New York, NY – February 27, 2017 – Sichenzia Ross Ference Kesner LLP announced today that it has represented XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL.TA), an Israeli clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, in a registered direct offering of 1,000,000 American Depository Shares (“ADSs”) at a price of $2.50 per share and unregistered warrants to purchase 1,000,000 ADSs at an exercise price of $4.10 per ADS for gross proceeds of $2,500,000. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. The Sichenzia Ross Ference Kesner LLP team was led by partners Gregory Sichenzia and Avital Even-Shoshan and counsel Cheryll Calaguio.
- Founding Partner Gregory Sichenzia Participates on CLE Webinar Examining PIPEs and Registered Direct Offerings - August 7, 2020
- Sichenzia Ross Ference LLP Represents Aegis Capital as Sole Bookrunner in $6 Million Public Offering of Avinger Inc. Common Stock - August 6, 2020
- Sichenzia Ross Ference LLP Represents ThinkEquity LLC in $10 Million Initial Public Offering of 1847 Goedeker Inc. Common Stock - August 5, 2020